C4 Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Tennessee, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
490 Arsenal Way Ste 120, Watertown, Tenn...Phone Number
(617) 231-0700Website
www.c4therapeutics.comRevenue
$35.9 MillionStock Symbol
CCCCIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About C4 Therapeutics
C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to transform how disease is treated. Our leadership team is comprised of experts in their fields, with experience spanning across leading biopharma organizations. Together, our team has experience in all the key disciplines needed to make new innovative technologies a reality for patients.Explore more
C4 Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is C4 Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if C4 Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when C4 Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at C4 Therapeutics
Earning: See what the market has to say on C4 Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if C4 Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if C4 Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
C4 Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once C4 Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to C4 Therapeutics
Compare insights from companies similar to C4 Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
C4 Therapeutics
$35.9M
51-200
Public
$425M
2015
Kendra AdamsChief Financial Officer & Head Corporate Affairs & Principal Accounting Officer
Company Profile Activity
Activity Insights
C4 Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
C4 Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about C4 Therapeutics.
C4 Therapeutics financials insights
Gather financial insights about C4 Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$73M
2020
Multiple Rounds
$352M
C4 Therapeutics Tech Stack
A closer look at the technologies used by C4 Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Lateral Move
Executive Move
Executive Moves, Lateral Move
Open Position
Hiring Plans
C4 Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Clinical Research, Clinical Trial Protocols, Investigator's Brochure, Clinical Research Operations, Clinical Trial Planning, Clinical Trials, and Clinical Data Management.
Hiring Plans
Open Position
C4 Therapeutics News & Media
C4 Therapeutics to Participate in Upcoming Conferences
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”),C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as recent business highlights.C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding C4 Therapeutics
Sign Up For FreeTo access detailed company insights
C4 Therapeutics is a clinical-stage biotechnology company developing a new generation of medicines that harness targeted protein degradation (TPD) to transform how disease is treated. Our leadership team is comprised of experts in their fields, with experience spanning across leading biopharma organizations. Together, our team has experience in all... Read More
